Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 12/20 | 0.65 |
| ▸ | GRM2 | Q14416 | 3/20 | 0.56 |
| ▸ | MAOB | P27338 | 2/20 | 0.48 |
| ▸ | FADS1 | O60427 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5931081 | 1.00 | MAOA (0.65) | MAOAGRM2MAOBFADS1KCNH2 | |
| SCHEMBL13298923 | 0.85 | MAOA (0.82) | MAOAKCNH2CYP3A4CYP2D6 | |
| SCHEMBL3326714 | 0.83 | MAOA (0.70) | MAOAMAOBKCNH2CYP3A4CYP2D6 | |
| SCHEMBL2849302 | 0.83 | MAOA (0.70) | MAOAMAOBKCNH2CYP3A4CYP2D6 | |
| SCHEMBL15630337 | 0.83 | GRM2 (0.49) | MAOAGRM2MAOBFADS1KCNH2 | |
| SCHEMBL16934432 | 0.83 | GRM2 (0.49) | MAOAGRM2MAOBFADS1KCNH2 | |
| SCHEMBL3325391 | 0.82 | MAOA (0.69) | MAOAMAOBKCNH2CYP3A4CYP2D6 | |
| SCHEMBL14410639 | 0.82 | MAOA (0.60) | MAOAGRM2MAOBKCNH2 | |
| SCHEMBL3367952 | 0.82 | MAOA (0.66) | MAOAMAOBKCNH2CYP3A4CYP2D6 | |
| SCHEMBL4017518 | 0.82 | MAOA (0.68) | MAOAMAOBKCNH2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137243-A1 | Oxazolidinone And/Or Isoxazoline As Antibacterial Agents | ASTRAZENECA AB (SE) | 2010-06-03 | — | — | US | disclosed |
| US-20100137243-A1 | Oxazolidinone And/Or Isoxazoline As Antibacterial Agents | ASTRAZENECA AB (SE) | 2010-06-03 | — | — | US | disclosed |
| US-20100137243-A1 | Oxazolidinone And/Or Isoxazoline As Antibacterial Agents | ASTRAZENECA AB (SE) | 2010-06-03 | — | — | US | disclosed |
| US-7473699-B2 | 3-cyclyl-5-(nitrogen-containing 5-membered ring)methyl-oxazolidinone derivatives and their use as antibacterial agents | ASTRAZENECA AB (SE) | 2009-01-06 | — | — | US | disclosed |
| US-7473699-B2 | 3-cyclyl-5-(nitrogen-containing 5-membered ring)methyl-oxazolidinone derivatives and their use as antibacterial agents | ASTRAZENECA AB (SE) | 2009-01-06 | — | — | US | disclosed |
| US-7396847-B2 | Oxazolidinone and/or isoxazoline as antibacterial agents | ASTRAZENECA AB (SE) | 2008-07-08 | — | — | US | disclosed |
| US-7396847-B2 | Oxazolidinone and/or isoxazoline as antibacterial agents | ASTRAZENECA AB (SE) | 2008-07-08 | — | — | US | disclosed |
| US-7157482-B2 | Antibacterial 1,3-oxazolidin-2-one derivatives | ASTRAZENECA AB (SE) | 2007-01-02 | — | — | US | disclosed |
| US-7157482-B2 | Antibacterial 1,3-oxazolidin-2-one derivatives | ASTRAZENECA AB (SE) | 2007-01-02 | — | — | US | disclosed |
| US-7157482-B2 | Antibacterial 1,3-oxazolidin-2-one derivatives | ASTRAZENECA AB (SE) | 2007-01-02 | — | — | US | disclosed |
| US-20060116400-A1 | Oxazolidinone and/or isoxazoline derivatives as antibacterial agents | ASTRAZENECA AB (SE) | 2006-06-01 | — | — | US | disclosed |
| US-20060084810-A1 | Antibacterial 1,3-oxazolidin-2-one derivatives | ASTRAZENECA AB (SE) | 2006-04-20 | — | — | US | disclosed |
| EP-1427711-B1 | OXAZOLIDINONE AND/OR ISOXAZOLINE DERIVATIVES AS ANTIBACTERIAL AGENTS | ASTRAZENECA AB (SE) | 2005-07-13 | — | — | EP | disclosed |
| US-20050119292-A1 | 3-Cyclyl-5-(nitrogen-containing 5-membered ring)methyl-oxazolidinone derivatives and their use as antibacterial agents | ASTRAZENECA AB (SE) | 2005-06-02 | — | — | US | disclosed |
| US-20050107435-A1 | Oxazolidinone and/or isoxazoline as antibacterial agents | ASTRAZENECA AB (SE) | 2005-05-19 | — | — | US | disclosed |
| EP-1497286-A1 | 3-CYCLYL-5-(NITROGEN-CONTAINING 5-MEMBERED RING) METHYL-OXAZOLIDINONE DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | Astrazeneca AB (SE) | 2005-01-19 | — | — | EP | disclosed |
| EP-1427711-A1 | OXAZOLIDINONE AND/OR ISOXAZOLINE DERIVATIVES AS ANTIBACTERIAL AGENTS | AstraZeneca AB (SE) | 2004-06-16 | — | — | EP | disclosed |
| WO-2003072575-A1 | 3-CYCLYL-5-(NITROGEN-CONTAINING 5-MEMBERED RING) METHYL-OXAZOLIDINONE DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | ASTRAZENECA AB (SE) | 2003-09-04 | — | — | WO | disclosed |
| WO-2003022824-A1 | OXAZOLIDINONE AND/OR ISOXAZOLINE AS ANTIBACTERIAL AGENTS | ASTRAZENECA AB (SE) | 2003-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137243-A1 | Oxazolidinone And/Or Isoxazoline As Antibacterial Agents | CYP8B1, HRH2, CYP2W1 | MAOA 482/4885GRM2 2199/4885MAOB 192/4885 |
| US-20060084810-A1 | Antibacterial 1,3-oxazolidin-2-one derivatives | HRH1, HDHD5, NGLY1 | MAOA 717/4885GRM2 4372/4885MAOB 898/4885 |
| US-20050107435-A1 | Oxazolidinone and/or isoxazoline as antibacterial agents | CYP8B1, CYP2W1, HRH2 | MAOA 800/4885GRM2 2354/4885MAOB 328/4885 |
| US-20060116400-A1 | Oxazolidinone and/or isoxazoline derivatives as antibacterial agents | NR0B2, NR0B1, HRH2 | MAOA 293/4885GRM2 856/4885MAOB 168/4885 |
| US-20050119292-A1 | 3-Cyclyl-5-(nitrogen-containing 5-membered ring)methyl-oxazolidinone derivatives and their use as antibacterial agents | H1-0, NGLY1, H1-5 | MAOA 1576/4885GRM2 4001/4885MAOB 992/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.